{
    "clinical_study": {
        "@rank": "146336", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the efficacy, safety, tolerability and patient\n      reported quality of life of Herceptin (trastuzumab) subcutaneous therapy in patients with\n      HER2-positive early breast cancer in routine clinical practice. Data from eligible patients\n      will be collected for the duration of their treatment (approximately 1 year) and for 1-2\n      years of follow-up."
        }, 
        "brief_title": "HerSCin: An Observational Study of Herceptin (Trastuzumab) Subcutaneous in Patients With HER2-Positive Early Beast Cancer", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female or male adult patient; >/= 18 years of age\n\n          -  Histologically confirmed adenocarcinoma of the breast\n\n          -  HER2-positive tumor\n\n          -  Eligible for neo-adjuvant or adjuvant treatment with Herceptin SC according to the\n             judgement of the physician Note: As of patient recruitment (date of patient informed\n             consent), retrospective documentation is allowed but limited to up to 9 weeks after\n             initial start of therapy with Herceptin SC\n\n        Exclusion Criteria:\n\n          -  Contraindications according to the Summary of Product Characteristics of Herceptin SC\n\n          -  Pregnant and breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with HER2-positive early breast cancer initiated on treatment with subcutaneously\n        administered Herceptin"
            }
        }, 
        "enrollment": {
            "#text": "960", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959386", 
            "org_study_id": "ML28759"
        }, 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mainz", 
                    "country": "Germany", 
                    "zip": "55131"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "CLINICAL PRACTICE SURVEILLANCE OF THE USE OF HERCEPTIN SUBCUTANEOUS IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER (HerSCin)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28759 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pathological complete response (pCR) rate (for patients treated in the neo-adjuvant setting)", 
                "safety_issue": "No", 
                "time_frame": "approximately 1 year"
            }, 
            {
                "measure": "Disease-free survival (DSF) rate after 2 years (for patients treated in the adjuvant setting)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Quality of life: EORTC QLQ-C30/QLQ-BR23 questionnaires", 
                "safety_issue": "No", 
                "time_frame": "approximately 1 year"
            }, 
            {
                "measure": "Herceptin dose/treatment schedule/administration", 
                "safety_issue": "No", 
                "time_frame": "approximately 1 year"
            }, 
            {
                "measure": "Concomitant chemotherapy/treatment/intervention", 
                "safety_issue": "No", 
                "time_frame": "approximately 1 year"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}